Defendant
1 case as defendant.
Fieldcure Co., Ltd. (also styled FieldCure; Korean: 주식회사 필드큐어) is a South Korean medical-device venture founded in October 2017 by CEO Dr. Myonggeun Yoon, a medical physicist and Korea University biomedical engineering professor. It is headquartered in Seongbuk-gu, Seoul (Anam-ro, in the Korea University area). The company is privately held and venture-backed (TIPS and Post-TIPS programs; a Series B round reported by The VC), with affiliated ties to Korea University's technology holding company. The VC lists roughly 15 employees as of mid-2026 and minimal reported revenue (about KRW 89 million in 2023), indicating a small, R&D-stage company.
Products / operations. FieldCure develops electric-field cancer therapy ("electroceutical") hardware and treatment-planning software based on its iMPACT technology — applying alternating electric fields to disrupt cancer cell division, with adjunct hyperthermia. Its disclosed offerings include the OncoField electric-field treatment platform and TPS planning software, the DeepField A460 and iMET electric-field cancer treatment systems, and the iField-PL150 hyperthermia device (Korean MFDS-approved 2025). It conducts clinical research with domestic and international hospitals and states plans to enter China, the US, and Europe. It is an operating company, not a non-practicing entity.
Patent-litigation posture. The structured data show one tracked case, with FieldCure as defendant and zero as plaintiff — the profile of an operating company targeted by a larger competitor's infringement suit, not an NPE. The suit was Novocure GmbH v. Fieldcure Co. Ltd., filed November 7, 2022 in the U.S. District Court for the Middle District of Florida (Tampa Division), asserting three Novocure patents ('699, '921, '203) covering Tumor Treating Fields electrodes and apparatus. Venue was Florida rather than an NPE-favored district, chosen because FieldCure allegedly planned to import and exhibit its device at the Society for Neuro-Oncology conference in Tampa in November 2022.
Disposition. Novocure voluntarily dismissed the case without prejudice on December 2, 2022, and the court closed it days later; no merits ruling is recorded. The dispute reflects competition in the electric-field cancer therapy space, where Novocure (Optune) is the established commercial player and FieldCure is an emerging Korean challenger developing alternative electrode and treatment-planning approaches.
Sources: FieldCure website (fieldcure.com), The VC company profile, Korea University Holdings, RPX Insight/dockets (M.D. Fla. 8:22-cv-02535).
Novocure GmbH sued Fieldcure Co. Ltd. for patent infringement alleging the Fieldcure Device, a TTFields device, infringed asserted patents including US 7,715,921. The case was voluntarily dismissed without prejudice on December 2, 2022, with no merits ruling on infringement, validity, or enforceability.